50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress ...Middle East

SHANGHAI, June 27, 2024 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced...

Hence then, the article about 50 orr impressive clinical trial data for irpagratinib combined with atezolizumab in advanced hepatocellular carcinoma stuns esmo gi congress was published today ( Friday 28/06/2024 - 05:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( 50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress )

Also on site :

• Germany’s Merz changes stance on Russia
• Tokyo's Yamanote Line suspended due to power outage
• Germany’s Merz acknowledges ‘strategic mistake’